To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

NCT04561817 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Evolving data with Ipatasertib that changes the known risk / benefit background in pursuing future studies.

Conditions

Interventions

Sponsor

Icahn School of Medicine at Mount Sinai